Trial · NCT07900191
Network-based tDCS for Apathy
NCT07900191, Not applicable, Not yet recruiting, Hebrew SeniorLife
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Network-based tDCS for Apathy. Trials, record NCT07900191. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07900191
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Network-based tDCS for Apathy
- NCT number
- NCT07900191
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 20 participants, estimated
- Lead sponsor
- Hebrew SeniorLife
- Conditions
- Apathy, Brain Stimulation, Dementia
- Interventions
- transcranial direct current stimulation, sham stimulation
- First posted
- 2026-10-28
- Last updated
- 2026-10-28
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Participant Retention Rate | Up to 2 weeks (from the first stimulation session through the immediate post-intervention assessment) | The metrics measures the compliance of the intervention participation by calculating the percentage of enrolled participants who complete the study, relative to the total number of enrolled participants. |
| Secondary | Blinding Efficacy | Immediately after the first session of stimulation, and immediately after 5 sessions of stimulation | Blinding efficacy will be assessed by asking participants to guess their treatment assignment (active, sham, or unsure) at the end of the intervention and calculating the percentage of participants who correctly identify their assigned group, incorrectly identify their assigned group, or report being unsure. |
| Secondary | Side Effects | Up to 2 weeks (from the first stimulation session through the immediate post-intervention assessment) | Side effects will be assessed using a standardized questionnaire documenting the occurrence, type, and severity of side effects associated with tDCS (e.g., tingling, itching, burning sensations, headache, or skin irritation). Results will be summarized as the percentage of participants reporting each side effect and its severity. |
| Secondary | Change in Apathy Evaluation Scale - Informant Version (AES-I) Score | Baseline and approximately Week 2 (within 3 days after the final stimulation session) | Apathy will be assessed using the 18-item Apathy Evaluation Scale - Informant Version (AES-I), completed by a knowledgeable informant or study partner. Each item is rated on a 4-point scale, yielding a total score ranging from 18 to 72, with higher scores indicating greater apathy. Changes in total scores from baseline will be used to evaluate changes in apathy severity. |
| Secondary | Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function Score | Baseline and approximately Week 2 (within 3 days after the final stimulation session) | Physical function will be assessed using the 6-item PROMIS Physical Function Short Form (6a). Raw scores range from 6 to 30 and will be converted to standardized T-scores, with higher scores indicating better physical functioning. Changes from baseline will be evaluated. |
| Secondary | Change in PROMIS Depression Score | Baseline and approximately Week 2 (within 3 days after the final stimulation session) | The 8-item PROMIS Depression Short Form (8a) will measure depressive symptoms, as completed by participants. Raw scores range from 8 to 40 and will be converted to standardized T-scores, with higher scores indicating greater depressive symptom severity. |
| Secondary | Change in PROMIS Ability to Participate in Social Roles and Activities Score | Baseline and approximately Week 2 (within 3 days after the final stimulation session) | Participation in social roles and activities will be assessed using PROMIS short-form questionnaires (8a and 4a), primarily completed by participants, with caregiver-proxy assessments used when necessary. Raw scores range from 8 to 40 for the 8a form and 4 to 20 for the 4a form. Scores will be converted to standardized T-scores, with higher scores indicating better ability to participate in social roles and activities. |
| Secondary | Change in Montreal Cognitive Assessment (MoCA) Score | Baseline and approximately Week 2 (within 3 days after the final stimulation session) | This metric will measure global cognitive function. Total scores range from 0 to 30, with higher scores indicating better cognitive function. Changes from baseline will be evaluated. |
| Secondary | Change in Alpha-Band Resting-State Electroencephalography (EEG) Functional Connectivity Between anterior cingulate cortex (ACC) and dorsolateral prefrontal cortex (DLPFC) | Baseline and approximately Week 2 (within 3 days after the final stimulation session) | Resting-state electroencephalography (EEG) will be used to assess alpha-band (8-13 Hz) functional connectivity between the anterior cingulate cortex (ACC) and dorsolateral prefrontal cortex (dlPFC). Functional connectivity will be quantified using the weighted Phase Lag Index (wPLI), with values ranging from 0 to 1 and higher values indicating stronger functional coupling between these regions. |
| Other | Caregiver-Reported Facilitators and Barriers to tDCS Intervention Implementation | Within 3 days after the final stimulation session. | Semi-structured interviews will be conducted with caregivers following the final tDCS session to identify perceived facilitators, barriers, and opportunities for improving the intervention. Guided by the Behavior Change Wheel framework, interviews will explore factors related to capability (physical and psychological), opportunity (physical and social), and motivation (reflective and automatic). Interview responses will be analyzed qualitatively to identify recurring themes related to intervention feasibility, acceptability, and potential improvements. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07900191
GET https://conductscience.org/api/trials/v1/NCT07900191/registered